Eli Lilly Reduces Zepbound Prices to Increase Access for Patients

Eli Lilly has announced a reduction in the price of its obesity treatment, Zepbound, to enhance affordability for U.S. patients. Starting immediately, patients with a prescription can purchase a monthly supply of the 2.5 mg dose for $299, a decrease from $349. The price for the 5 mg dose has also been lowered to $399, down from $499. Additionally, the higher doses are now priced at $449 per month under Lilly’s Zepbound Self Pay Journey Program, a significant reduction from the previous cost of $499.

These changes come shortly after Eli Lilly announced similar price cuts for its multi-dose pens, which are pending approval from the U.S. Food and Drug Administration (FDA). According to Eli Lilly executive Ilya Yuffa, “Far too many people who need obesity treatments still face cost and coverage barriers.” This sentiment underscores the company’s commitment to making vital medications more accessible.

The price adjustments align with a growing demand for weight-loss therapies, which has significantly boosted Eli Lilly’s market presence. The Indianapolis-based company recently achieved a milestone by becoming the first drug manufacturer to attain a market value of $1 trillion, a feat previously reserved for major technology firms. Eli Lilly’s stock has surged by more than 39 percent this year, driven by the explosive growth in the market for obesity medications.

Sales of Eli Lilly’s tirzepatide, marketed as Zepbound for obesity and Mounjaro for diabetes, have positioned it as the world’s best-selling drug, surpassing Merck’s cancer treatment, Keytruda. Zepbound is specifically approved for adults with obesity or overweight conditions, as well as for those suffering from moderate-to-severe obstructive sleep apnea.

In November 2023, Eli Lilly entered into an agreement with the administration of former U.S. President Donald Trump to lower prices for its popular GLP-1 medications under Medicare and Medicaid programs, along with options for cash payers. This initiative reflects the company’s proactive approach to addressing the rising costs of healthcare and the increasing need for effective obesity treatments.

Eli Lilly’s decision to reduce prices for Zepbound is part of a broader strategy to improve access to essential medications while navigating the complexities of a rapidly evolving healthcare landscape. As demand for weight-loss therapies continues to rise, the company’s actions may significantly impact patient access and affordability in the coming months.